Immature Reticulocyte Fraction (IRF%): a guide

What is IRF%

The Immature Reticulocyte Fraction (IRF%) is a marker that shows what proportion of all reticulocytes are the youngest — that is, those containing the most RNA (ribonucleic acid). These cells are the first to be released from the bone marrow into the blood, making IRF% an early signal of bone marrow activity.

Analyzers divide reticulocytes into three fractions based on RNA content: MFR (medium fluorescence ratio) and HFR (high fluorescence ratio) — both make up IRF. LFR (low fluorescence ratio) — these are already mature cells, comprising LFR%. IRF% = MFR% + HFR%.

Important: IRF% rises faster than overall RET% or RET#, because the youngest reticulocytes appear in the blood before they mature into standard reticulocytes.

Reference ranges

The normal range for adults is typically 2–14%. Ranges may differ for children and newborns. Different analyzers may use slightly different norms, so always evaluate against your laboratory's stated reference range.

Why IRF% may be elevated

An elevated IRF% means the bone marrow is being actively stimulated and releasing more of the youngest reticulocytes:

• Recovery from anaemia treatment — IRF% rises before RET% and haemoglobin increase, making it an early indicator of treatment effectiveness.
• Active bleeding or haemolysis — the body responds by accelerating red blood cell production.
• Recovery after chemotherapy or bone marrow transplantation — a rise in IRF% is one of the first signs of marrow reconstitution.
• Erythropoietin (EPO) therapy for kidney disease or anaemia stimulates the production of the youngest reticulocytes.

Why IRF% may be low

A low IRF% indicates that the bone marrow is producing few or no new red blood cells:

• Aplastic anaemia — bone marrow activity is suppressed or completely halted.
• Severe iron, vitamin B12, or folate deficiency — without building materials, production stops.
• Myelodysplastic syndrome — production disorders due to cell mutations.
• Drug-induced marrow suppression — chemotherapy, immunosuppressants, or other drugs can directly reduce IRF%.

What to do next

IRF% is most valuable alongside RET#, RET%, haemoglobin, and MCV. IRF% changes alone are not sufficient for a diagnosis, but this marker enables the earliest detection of changes in bone marrow response — even before other markers have changed.

If a doctor prescribes anaemia treatment and wants to assess response early, IRF% is the most appropriate tool: it rises within 3–5 days of effective treatment starting.

Monitoring over time

IRF% is particularly valuable for monitoring treatment progress:

• During iron therapy, IRF% rises within 3–5 days — this is the earliest indicator of treatment response.
• After bone marrow transplantation, a rise in IRF% is one of the first signs of engraftment — it is observed earlier than the general reticulocyte count.
• During EPO therapy, monitoring IRF% allows assessment of whether treatment for kidney disease or anaemia is working.

Questions for your doctor

• What does my current IRF% indicate about bone marrow activity?
• Can IRF% changes be used to assess my treatment response early?
• Are additional tests needed, such as RET# or ferritin, to better understand the result?
• How often should IRF% be monitored if I am starting anaemia treatment?